Log in

Relevant bibliographies by topics / H. Lee Moffitt Cancer Center and Research Institute

Contents

Journal articles

Academic literature on the topic 'H. Lee Moffitt Cancer Center and Research Institute'

Author: Grafiati

Published: 4 June 2021

Last updated: 28 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'H. Lee Moffitt Cancer Center and Research Institute.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "H. Lee Moffitt Cancer Center and Research Institute"

1

C. Geppner, MLS, CTTS, PA-C, Alexis. "Targeting p53 in MDS: Highlights From SOHO 2021." Journal of the Advanced Practitioner in Oncology 13, no. 1 (2022): 15–16. http://dx.doi.org/10.6004/jadpro.2022.13.1.12.

Full text

Abstract:

Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, evaluates data from the session on p53 in myelodysplastic syndrome presented by David A. Sallman, MD, of H. Lee Moffitt Cancer Center and Research Institute, at the 2021 SOHO Annual Meeting.

APA, Harvard, Vancouver, ISO, and other styles

2

Sutphen, Rebecca, Yan Xu, George D. Wilbanks, et al. "Lysophospholipids Are Potential Biomarkers of Ovarian Cancer." Cancer Epidemiology, Biomarkers & Prevention 13, no. 7 (2004): 1185–91. http://dx.doi.org/10.1158/1055-9965.1185.13.7.

Full text

Abstract:

Abstract Objective: To determine whether lysophosphatidic acid (LPA) and other lysophospholipids (LPL) are useful markers for diagnosis and/or prognosis of ovarian cancer in a controlled setting. Method: Plasma samples were collected from ovarian cancer patients and healthy control women in Hillsborough and Pinellas counties, Florida, and processed at the University of South Florida H. Lee Moffitt Cancer Center and Research Institute (Moffitt). Case patients with epithelial ovarian cancer (n = 117) and healthy control subjects (n = 27) participated in the study. Blinded LPL analysis, including

APA, Harvard, Vancouver, ISO, and other styles

3

Albrecht, Terrance L., Christina Blanchard, John C. Ruckdeschel, Michael Coovert, and Rebecca Strongbow. "Strategic Physician Communication and Oncology Clinical Trials." Journal of Clinical Oncology 17, no. 10 (1999): 3324–32. http://dx.doi.org/10.1200/jco.1999.17.10.3324.

Full text

Abstract:

PURPOSE: Clinical trials are the primary means for determining new, effective treatments for cancer patients, yet the number of patients that accrue is relatively limited. The purpose of this study was to explore the relationship between physician behavior and patient accrual to a clinical trial by videotaping the interaction. PATIENTS AND METHODS: Forty-eight patient-physician interactions involving 12 different oncologists were videotaped in several clinics at the H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL). The purpose of each interaction was to present the possibility o

APA, Harvard, Vancouver, ISO, and other styles

4

Walker-Mimms, Hannah L., Nicole Londono, Yi Liao, et al. "Abstract A060 Investigating underlying efficacy and mechanism of action of the KIF11 inhibitor filanesib in Ewing and clear cell sarcomas." Cancer Research 84, no. 17_Supplement (2024): A060. http://dx.doi.org/10.1158/1538-7445.pediatric24-a060.

Full text

Abstract:

Abstract Ewing (ES) and clear cell (CCS) sarcomas are bone and soft tissue malignances and in advanced and relapsed disease overall survival rates remain dismal. For metastatic ES, five-year survival rates are between 15% and 30%. In CCS, the five-year survival rates are between 30% and 67%. Accordingly, there is a critical need for the development of novel targeted therapeutics for the treatment of these rare cancers. Both cancers are driven by fusion proteins; EWS-FLI1 in ES and EWS-ATF1 in CCS, which arise from separate chromosomal translocations: t(11;22)(q24;q12) and t(12;22)(q13;q12) res

APA, Harvard, Vancouver, ISO, and other styles

5

Yacoub, Abraham Tareq, Jayasree Krishnan, Ileana M. Acevedo, Joseph Halliday, and John Norman Greene. "NUTRITIONALLY VARIANT STREPTOCOCCI BACTEREMIA IN CANCER PATIENTS: A RETROSPECTIVE STUDY, 1999-2014." Mediterranean Journal of Hematology and Infectious Diseases 7 (April 19, 2015): e2015030. http://dx.doi.org/10.4084/mjhid.2015.030.

Full text

Abstract:

BackgoundNutritionally variant Streptococci (NVS), Abiotrophia and Granulicatella are implicated in causing endocarditis and blood stream infections more frequently than other sites of infection. Neutropenia and mucositis are the most common predisposing factors for infection with other pathogens in cancer patients. In this study we investigated the clinical characteristics of NVS bacteremia in cancer patients and identified risk factors and outcomes associated with these infections. Materials and MethodsWe retrospectively reviewed all cases of NVS bacteremia occurring from June 1999 to April

APA, Harvard, Vancouver, ISO, and other styles

6

Schabath, Matthew B. "Abstract IA018: Sexual orientation and gender identity (SOGI) collection: Experiences at an NCI-Designated Cancer Center." Cancer Epidemiology, Biomarkers & Prevention 32, no. 12_Supplement (2023): IA018. http://dx.doi.org/10.1158/1538-7755.disp23-ia018.

Full text

Abstract:

Abstract Wide-spread collection of sexual orientation and gender identity (SOGI) data has been a barrier to conduct of research to identify disparities and inequitable cancer care among sexual and gender minority (SGM) populations. Additionally, lack of SOGI data in electronic health records (EHR) renders clinical care teams unable to integrate such information into appropriate and tailored care and treatment plans and may delay the establishment of respectful, affirming, and knowledgeable relationships between patients and their cancer care teams, and the institutions in which they receive he

APA, Harvard, Vancouver, ISO, and other styles

7

Morrill, Susanne, Daniza Mandich, Richard Cartun, and Andrew L. Salner. "Implementation of a high-quality biospecimen program to support molecular medicine." Journal of Clinical Oncology 31, no. 31_suppl (2013): 200. http://dx.doi.org/10.1200/jco.2013.31.31_suppl.200.

Full text

Abstract:

200 Background: The successful implementation of a tumor genomics program relies heavily upon the collection of high quality tumor tissue samples. Although there has been an evolution towards utilizing formalin-fixed paraffin embedded (FFPE) tissue, many research centers continue to rely upon frozen fresh tissue for these types of analyses. A comprehensive effort is required to supply high-volume and high-quality tissue for research. Most community hospitals, even with superb pathology departments, are not well suited to deliver consistent tissue samples without a concerted programmatic effort

APA, Harvard, Vancouver, ISO, and other styles

8

Walker-Mimms, Hannah L., Nicole Londono, Yi Liao, et al. "Abstract 647: FDA approved library screen revealed Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types." Cancer Research 84, no. 6_Supplement (2024): 647. http://dx.doi.org/10.1158/1538-7445.am2024-647.

Full text

Abstract:

Abstract There is a compelling need for the development of more effective and less toxic therapies for patients with Ewing Sarcoma (ES) and Clear Cell Sarcoma (CCS). ES and CCS are characterized by chromosomal translocations which result in two distinct fusion proteins: EWS-ATF1 (t(12;22)(q13;q12)) in CCS and EWS-FLI1 (t(11;22)(q24;q12)) in ES. There is a strong premise that targeting the fusion proteins or their key downstream signaling pathways will be disease modifying and improve outcomes for patients. Preliminary high throughput screening studies using an FDA approved small molecule compo

APA, Harvard, Vancouver, ISO, and other styles

9

Palve, Vinayak C., Hannah L. Walker-Mimms, Ritu Chaudhary, et al. "Abstract 3368: Combination of a chk1/2 dual inhibitor (prexasertib) and gemcitabine reveals a novel intrinsic synergy mechanism in head and neck squamous cell carcinoma." Cancer Research 84, no. 6_Supplement (2024): 3368. http://dx.doi.org/10.1158/1538-7445.am2024-3368.

Full text

Abstract:

Abstract Head and neck squamous cell carcinoma (HNSCC) presents a challenging clinical scenario due to its recurrence propensity despite existing treatments. Altered intrinsic signaling pathways significantly contribute to therapeutic resistance, demanding exploration of novel strategies to induce tumor cell demise. Dysregulated cell cycle and DNA damage repair constitute pivotal events driving HNSCC progression, offering potential therapeutic targets.CHK1 and CHK2, pivotal regulators of the DNA replication checkpoint, are promising targets in HNSCC. The convergence of DNA-damaging agents with

APA, Harvard, Vancouver, ISO, and other styles

10

Strickland-Marmol, Leah B., Andras Khoor, Sandra K. Livingston, and Amyn Rojiani. "Utility of Tissue-Specific Transcription Factors Thyroid Transcription Factor 1 and Cdx2 in Determining the Primary Site of Metastatic Adenocarcinomas to the Brain." Archives of Pathology & Laboratory Medicine 131, no. 11 (2007): 1686–90. http://dx.doi.org/10.5858/2007-131-1686-uottft.

Full text

Abstract:

AbstractContext.—Brain metastases of adenocarcinoma of unknown primary pose a diagnostic dilemma to the surgical pathologist. Although the most common source in these cases is the lung, determining a primary source is difficult on routinely stained slides. Immunohistochemical stain panels including differential cytokeratins, hormone receptors, and breast-specific proteins are commonly used in these cases. Recently, attention has turned to tissue-specific transcription factors, such as thyroid transcription factor 1 (TTF-1) and Cdx2, in the appraisal of metastatic adenocarcinomas.Objective.—To

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!